What Refzil-O Treats: Main Uses and Benefits

Refzil-O (Cefprozil) is commonly used to help manage symptoms related to systemic imbalance and is applied across domains where additional symptomatic support is needed against acute bacterial infections. It is relevant in clinical settings that involve acute or unstable symptom patterns across several therapeutic domains.

The medication is commonly used across conditions presenting with acute episodes, such as pharyngitis, tonsillitis, otitis media, and acute sinusitis. It is also applied in addressing conditions marked by increased physiological stress, such as acute bacterial exacerbations of chronic bronchitis, and for uncomplicated skin and urinary tract infections.

Refzil-O is commonly used when short-term symptomatic assistance is needed, such as for symptoms related to systemic imbalance, localized pain, or increased discomfort. It helps address symptom clusters that may become intense or disruptive, assisting with maintaining functional stability when symptoms are more noticeable.

“Refzil-O is used to help with symptomatic relief in conditions where bacterial presence causes significant discomfort and systemic response, supporting the patient during these difficult episodes.”

---

Quick Fact: Support for Acute Symptomatic Manifestations

Regulatory References

1. DailyMed - NIH

Eligibility Profile for Refzil-O (Cefprozil)

This section outlines the eligibility and non-eligibility requirements for using Refzil-O, based strictly on official government regulatory documents.

Absolute Contraindications

Refzil-O must not be used by individuals with a confirmed allergy or known hypersensitivity to Cefprozil itself or to any antibiotic belonging to the cephalosporin class.

Populations Requiring Restricted or Conditional Use

Usage requires caution and clinical consideration in the following groups:

• History of Penicillin Allergy: Caution is necessary due to the risk of cross-sensitivity reactions among beta-lactam antibiotics.
• Severely Impaired Renal Function ( CrCl le 30 mL/min): A reduction in dosage is required for these patients to manage plasma concentrations.
• History of Colitis or Gastrointestinal Disease: Use with caution due to the risk of Clostridium difficile-associated diarrhea (CDAD).
• Phenylketonuria (PKU): The oral suspension formulation contains phenylalanine and must be used with caution.

Age and Physiological Status

Population	Eligibility Status
Infants under 6 months	Not recommended; safety and effectiveness are not established.
Pregnancy	Category B; use only if clearly needed, as human studies are inadequate.
Lactation (Breastfeeding)	Use with caution; small amounts are excreted into human milk.

Eligibility is primarily determined by ruling out known hypersensitivity and managing risk in populations with specific pre-existing conditions or developmental limitations.

Interactions with other medicines and products

The interaction profile of Refzil-O (Cefprozil) is documented by regulatory authorities based on pharmacokinetic and pharmacodynamic outcomes.

Formally Restricted Combinations

Co-administration is formally restricted with certain Live Bacterial Vaccines (such as Cholera and BCG vaccines). This combination is prohibited due to pharmacodynamic antagonism that may decrease the effectiveness of the vaccines. Mandatory timing rules require separation of Cefprozil administration from these vaccines by periods ranging from 3 to 14 days, as noted in official labeling.

Alterations in Systemic Exposure

The use of the uricosuric agent Probenecid is officially documented to inhibit Cefprozil's renal tubular clearance. This pharmacokinetic outcome results in a significant increase, specifically a doubling of the drug's Area Under the Curve (AUC), leading to higher systemic exposure. Furthermore, in patients with renal impairment, clearance is reduced, which officially results in prolonged plasma antibiotic concentrations.

Pharmacodynamic and Administration Notes

An additive risk profile is documented with certain co-administered agents. The co-use of Aminoglycoside Antibiotics is associated with an increased risk of nephrotoxicity. Additionally, the drug may increase the anticoagulant effects of Vitamin K Antagonists (e.g., Warfarin). Cefprozil is noted to potentially decrease the effectiveness of Hormonal Contraceptives. The bioavailability of Cefprozil is not significantly affected by food or antacids. The oral suspension formulation contains phenylalanine and must be accounted for by individuals with Phenylketonuria (PKU).

Refzil-O (Cefprozil) is a bactericidal antibiotic that acts through the inhibition of bacterial cell wall synthesis. Upon entry into the bacterial cell, it selectively targets and binds to specific high-molecular-weight penicillin-binding proteins (PBPs), primarily PBP 2 and PBP 3, which are anchored to the inner membrane of susceptible bacteria.

Refzil-O is a beta-lactam structure that functions as an acylating agent, forming a stable, covalent bond with the active site of these enzymes. By irreversibly inhibiting PBP function, the drug prevents the essential transpeptidation reaction. This reaction is required for the cross-linking of peptidoglycan polymers, which provide the structural rigidity of the cell wall. The resulting wall structure is defective and mechanically unstable, leading to a loss of osmotic balance. This failure results in the accumulation of high turgor pressure, culminating in rapid bacterial cell lysis and subsequent dissolution.

Refzil-O (Cefprozil) is an oral medication, available in tablet form (250 mg and 500 mg strengths) or as a powder that must be reconstituted to form an oral suspension (125 mg/5 mL and 250 mg/5 mL). The administration protocol involves the oral route exclusively and permits the dose to be taken with or without food, as food intake does not alter the extent of the drug's systemic delivery. The powder form requires careful preparation and the suspension must be shaken well before each measured dose.

Dosing frequency is standardized to either once daily ( q24 h) or twice daily ( q12 h), and the treatment duration is typically set at 10 days for most infections. For example, standard adult dosing for pharyngitis is 500 mg once daily, while acute bacterial exacerbation of chronic bronchitis is typically 500 mg twice daily.

There are modifications for certain patient populations. In cases of renal impairment where the creatinine clearance is 30 mL/min or less, the administered dose is reduced to 50% of the usual regimen, maintaining the same frequency. Conversely, no dose adjustment is required for patients with hepatic impairment or based on advanced age alone. Pediatric dosing (for children 6 months to 12 years) is determined based on body weight and must not exceed the maximum dose specified for adults. This protocol ensures the medicine is used procedurally according to specified parameters.

Research Evidence / Overview of Studies for Refzil-O

The clinical evaluation of Refzil-O (Cefprozil) is founded on a research base built primarily upon controlled clinical investigations and comparative clinical trials. These studies were used to explore and monitor Cefprozil in research contexts involving established anti-infective agents for specific bacterial conditions. Research examined two main outcomes: changes in symptoms (clinical response) and the elimination of the specific bacteria causing the infection (bacteriological response).

Evidence for Use in Respiratory Tract Infections

Research examined Cefprozil in conditions associated with acute or disruptive episodes, such as pharyngitis/tonsillitis, acute otitis media (AOM), and acute bacterial exacerbation of chronic bronchitis (ABECB). Studies explored outcomes related to physical discomfort and overall resolution. In trials exploring how symptoms change over time, studies reported patterns where one treatment group registered a higher rate of favorable clinical responses than the comparison group (penicillin V). Data show patterns related to the measured rate of bacterial pathogen elimination that were consistent across the studied treatments. For AOM and ABECB, published reviews of trials reported clinical success rates that were evaluated alongside other established anti-infective agents.

Evidence for Use in Uncomplicated Skin and Urinary Tract Infections

Clinical investigations also explored Cefprozil's activity in treating uncomplicated infections of the skin and skin structure (SSSI) and the lower urinary tract (UTI). These were short-term studies that assessed outcomes related to systemic or functional imbalance. The research base largely consists of comparative trials that assessed the medicine against established treatments. These studies reported measurements of clinical success and bacterial eradication rates that were observed in conjunction with the comparator drugs. The data focuses exclusively on uncomplicated infections.

Research Gaps and What Remains Uncertain

Research limitations and evidence gaps exist that help contextualize what is currently known about Cefprozil. The established evidence for the medicine is insufficient in pediatric patients younger than six months of age. Official bodies note that substantial data establishing the medicine’s activity in the subsequent prevention of rheumatic fever are not available at present. Furthermore, data for complex, chronic, or recurrent infection types remain insufficient.

Key Studies & References

1. Ava-Cefprozil - Product Monograph (Health Canada)
2. Review of Cefprozil Trials - NCBI Bookshelf

Common questions about Refzil-O (FAQ)

---

Q: Is Refzil-O in the same category as penicillin?

Refzil-O (Cefprozil) is classified as a cephalosporin antibiotic. According to official regulatory labeling, caution is advised for patients with a history of penicillin allergy. This is due to the potential for cross-sensitivity reactions among beta-lactam antibiotics, the broader class to which both cephalosporins and penicillins belong.

Q: Can people with diabetes use Refzil-O?

Regulatory documents do not list diabetes as a contraindication or population requiring dose adjustment for Refzil-O. However, official information does state that the use of cefprozil may result in a false-positive reaction when testing for glucose in the urine with certain methods. Individuals managing diabetes may want to be aware of this potential laboratory test artifact.

Q: Does Refzil-O cause stomach upset more than other antibiotics?

The most commonly noted reactions observed in clinical trials involved the gastrointestinal system, including diarrhea, nausea, vomiting, and abdominal pain. Official product information lists these reactions, but does not provide comparisons or claims about whether Refzil-O causes these effects more often than other antibiotics.

Q: Does Refzil-O affect blood sugar levels?

Regulatory documents state that Refzil-O may lead to a false-positive result for glucose when testing urine using certain methods. The product information does not specifically indicate that the medicine physiologically affects the actual level of glucose in the blood.

Q: What official documents describe who should not use Refzil-O?

Information detailing who should not use Refzil-O, including absolute contraindications and requirements for dose modifications, is found in official regulatory documents. These are documents such as the FDA Prescribing Information (or Full Prescribing Information) and the comprehensive drug monographs available through DailyMed.

Q: What studies have examined Refzil-O's efficacy against specific bacteria?

Studies and official product information detail the specific microorganisms that Cefprozil is active against in clinical settings. For example, for common infections like pharyngitis or tonsillitis, the drug is studied against susceptible bacteria such as Streptococcus pyogenes.

Q: How quickly does Refzil-O typically start working?

The drug is designed to act upon administration, and pharmacokinetic data provides insights into its absorption rate. Official information indicates that Refzil-O reaches its highest concentration in the bloodstream approximately 1.5 hours after an oral dose is taken by a fasting adult subject.

Q: Is Refzil-O known to cause any long-term side effects?

In regulatory documents, most non-serious side effects reported in studies are described as reversible upon discontinuation of the medication. The possibility of long-term or irreversible effects is not typically discussed in standard official labeling.

Q: Are there other brand names for the active ingredient in Refzil-O?

The active ingredient in Refzil-O is Cefprozil. The active ingredient, Cefprozil, may be marketed under different brand names depending on the region, all of which are documented in regulatory drug descriptions.

Q: How long after taking Refzil-O does it stay in your system?

According to pharmacokinetic data found in regulatory documents, the drug's plasma elimination half-life in normal adult subjects is approximately 1.3 hours. This measurement describes the time it takes for the concentration of the medicine in the blood to decrease by half.

Q: What happens if a person misses a dose of Refzil-O?

Instructions for a missed dose are outlined in the patient information leaflet, generally advising an individual to reference the timing of their next scheduled dose. Patient instructions typically provide guidance to avoid taking an extra dose to make up for a missed one.

Q: Does taking Refzil-O cause sensitivity to the sun?

Official regulatory documents do not list photosensitivity or sun sensitivity as a common or frequent side effect. However, the product information does report other serious skin reactions, such as Stevens-Johnson syndrome, observed in postmarketing surveillance.

Q: Why is it important to complete the full course of Refzil-O?

Official guidance states that taking the full course of medication is intended to minimize the development of drug-resistant bacteria and to support the treatment's full intended action against the infection.

Q: Is Refzil-O an antibiotic that is often associated with drug resistance?

Official product labeling for Refzil-O includes a prominent statement advising that the drug should be used only to treat infections proven or strongly suspected to be caused by susceptible bacteria. The caution in the official labeling is intended to reduce the development of drug-resistant bacteria over time.

Q: Are there any known interactions between Refzil-O and alcohol?

While there is no formal contraindication against alcohol use in regulatory labeling, some patient information sources note that general caution is often mentioned. This is because alcohol consumption may increase the risk of certain side effects already associated with the drug, such as dizziness or drowsiness.

Storage and Disposal Requirements for Cefprozil (Refzil-O)

Dosage Form	Required Storage Condition	Stability/Shelf-Life
Tablets	Controlled Room Temperature (20 C to 25 C); Protect from light, heat, moisture, and freezing.	Not specified in relation to packaging opening.
Oral Suspension (Reconstituted)	Refrigerated (2 C to 8 C); Do not freeze.	Must be discarded after 14 days.

All forms of Cefprozil must be stored out of the reach of children. The tablets must be kept in a closed container.

Disposal

Disposal of unused or expired medicine should follow official guidelines. The preferred method is using a drug take-back program. If this is unavailable, the medicine should be mixed with an undesirable substance (such as used coffee grounds) and sealed in a container before being placed in the household trash. Cefprozil is not on the list of medicines recommended for flushing down the toilet.